000076046 001__ 76046
000076046 005__ 20200117221610.0
000076046 0247_ $$2doi$$a10.1016/j.eimc.2017.10.024
000076046 0248_ $$2sideral$$a109066
000076046 037__ $$aART-2018-109066
000076046 041__ $$aeng
000076046 100__ $$aLorente, L.
000076046 245__ $$aSerum melatonin levels during the first seven days of severe sepsis diagnosis are associated with sepsis severity and mortality
000076046 260__ $$c2018
000076046 5060_ $$aAccess copy available to the general public$$fUnrestricted
000076046 5203_ $$aObjective: Higher serum melatonin levels have previously been found in patients with severe sepsis who died within 30 days of diagnosis than in survivors. The objective of our study were to determine whether serum melatonin levels during the first seven days of severe sepsis diagnosis could be associated with sepsis severity and mortality.
Methods: Multicentre study in eight Spanish Intensive Care Units which enrolled 308 patients with severe sepsis. We determined serum levels of melatonin, malondialdehyde (as biomarker of lipid peroxidation) and tumor necrosis factor-alpha at days 1, 4 and 8 of severe sepsis diagnosis. The study's primary endpoint was 30-day mortality.
Results: A total of 103 patients had died and 205 survived at 30 days of severe sepsis diagnosis, with the non-survivors presenting higher serum melatonin levels at days 1 (p<0.001), 4 (p<0.001) and 8 (p<0.001) of severe sepsis diagnosis than the survivor patient group. The multiple logistic regression analysis found that serum melatonin levels at days 1, 4 and 8 of severe sepsis diagnosis (p<0.001, p = 0.01 and p = 0.001, respectively) were associated with mortality adjusted for age, serum lactic acid, SOFA score and diabetes mellitus.
Conclusions: The novel and more interesting findings of our study were that serum melatonin levels during the first seven days of severe sepsis diagnosis are associated with sepsis severity and mortality. (C) 2017 Elsevier Espana, S.L.U. and Sociedad Espanola de Enfermedades lnfecciosas y Microbiologia Clinica.
000076046 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/PI14-00220
000076046 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000076046 590__ $$a1.685$$b2018
000076046 591__ $$aMICROBIOLOGY$$b106 / 133 = 0.797$$c2018$$dQ4$$eT3
000076046 591__ $$aINFECTIOUS DISEASES$$b72 / 89 = 0.809$$c2018$$dQ4$$eT3
000076046 592__ $$a0.348$$b2018
000076046 593__ $$aMicrobiology (medical)$$c2018$$dQ3
000076046 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000076046 700__ $$aMartin, M.M.
000076046 700__ $$aAbreu-Gonzalez, P.
000076046 700__ $$aPerez-Cejas, A.
000076046 700__ $$aLopez, R.O.
000076046 700__ $$aFerreres, J.
000076046 700__ $$aSole-Violan, J.
000076046 700__ $$0(orcid)0000-0002-3312-9383$$aLabarta, L.$$uUniversidad de Zaragoza
000076046 700__ $$aDiaz, C.
000076046 700__ $$aLlanos, C.
000076046 700__ $$aJimenez, A.
000076046 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000076046 773__ $$g36, 9 (2018), 544-549$$pEnferm. infecc. microbiol. clín.$$tEnfermedades Infecciosas y Microbiologia Clinica$$x0213-005X
000076046 8564_ $$s365113$$uhttps://zaguan.unizar.es/record/76046/files/texto_completo.pdf$$yPostprint
000076046 8564_ $$s16151$$uhttps://zaguan.unizar.es/record/76046/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000076046 909CO $$ooai:zaguan.unizar.es:76046$$particulos$$pdriver
000076046 951__ $$a2020-01-17-21:48:27
000076046 980__ $$aARTICLE